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bstract
ntroduction  Musculoskeletal conditions are the single largest contributor to years lived with disability worldwide. Most musculoskeletal
onditions can be managed in primary care, but for a small proportion of these patients the symptoms are caused by serious pathology.
lthough the general practitioner usually performs initial screening for serious pathology, evaluation and treatment by physiotherapists are
ften part of the treatment pathway. It is however unclear, how many patients in primary care physiotherapy have symptoms caused by serious
athology.
bjective  To estimate the prevalence of neoplasm, cauda equina syndrome, spinal fracture, infection and inflammatory pathology among
atients referred for musculoskeletal physiotherapy.
ethods  The study was a nationwide register-based cohort study. The authors identified all referrals for primary care musculoskeletal
hysiotherapy in the Danish National Health Insurance Service Register from 2014 to 2017. Records of hospital contacts were extracted
rom the Danish National Patient Register within 180 days from first physiotherapy contact, identifying all diagnoses of serious pathology.
revalence estimates of the serious pathology categories were reported.
esults  A total of 1 568 704 courses of treatment were included in the analysis. The overall prevalence of serious pathology was 2.30%. The
revalence of neoplasm was 2.11%, cauda equina syndrome 0.01%, fractures 0.13%, infections 0.01% and inflammatory pathology 0.06%.
igher prevalence’s were observed among patients with a previous history of serious pathology, aged above 50 and with comorbidites.
onclusions  Although serious pathology among patients referred by the General Practitioner to musculoskeletal physiotherapy is rare, the
resent study found an overall prevalence of serious pathology which exceeded the guideline endorsed prevalence estimates.
 2021 Published by Elsevier Ltd on behalf of Chartered Society of Physiotherapy.
eywords: Serious pathology; Prevalence; Primary care; Physiotherapy; Musculoskeletal conditions
w
i
ntroductionMusculoskeletal conditions are the single largest con-
ributor to years lived with disability worldwide [1]. These
onditions are typically characterized by pain and disability,
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031-9406/© 2021 Published by Elsevier Ltd on behalf of Chartered Society of Phhich may have substantial consequences for the affected
ndividual causing reduced ability to work or limited partic-
pation in social activities [2]. Most of the musculoskeletal
onditions are considered benign and non-specific. However,
 small proportion of patients with musculoskeletal condi-
ions have an undiscovered serious pathology causing their
ymptoms [3]. Previously, serious pathology among patients
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pecific pathologies, such as spinal malignant neoplasms,
ractures, cauda equine syndrome, spinal infections and axial
pondyloarthritis [4,5]. Early identification of these serious
athologies is of great importance because they necessitate
imely and correct diagnosis and treatment, which cannot be
rovided in primary care settings [3].
Initial screening for these serious pathologies is pri-
arily described in spine specific guidelines [3–5], but it
s important for all musculoskeletal conditions. It is com-
only acknowledged, that serious pathology in the group of
atients with musculoskeletal conditions is rare. Historically
he prevalence of serious pathology has been investigated in
opulations with spine specific conditions, and a more gen-
ral prevalence in the group of patients with musculoskeletal
onditions is yet to be estimated. European guidelines sug-
ests that 1% of LBP patients in primary care have a serious
athology causing their musculoskeletal symptoms [3,4]. Of
hese serious pathologies, fractures and malignancy are most
ommon, while cauda equina syndrome and spinal infections
re less common with an estimated prevalence of 0.04% and
.01% respectively [6].
Although the initial screening for serious pathology in pri-
ary care is usually performed by the General Practitioner
GP), direct access for physiotherapy treatment is increas-
ngly being implemented. Also, other healthcare providers
ay play a central role in the treatment pathway. In Denmark,
P’s acts as gatekeepers into the healthcare system, mean-
ng most patients with musculoskeletal conditions seek their
P, who then examine and refer the patient to appropriate
reatment. Often this treatment will include primary care
hysiotherapy. While screening for signs and symptoms of
erious pathologies is also part of the physiotherapy guide-
ines, no studies have yet investigated how many patients
iagnosed with serious pathology have been treated in pri-
ary care physiotherapy. Thus, the objective of this study
as to estimate the prevalence of neoplasm, cauda equina
yndrome, spinal fractures, infections and inflammatory
athology in patients referred for musculoskeletal physio-
herapy treatment.
ethods
esign  and  registers
The study was a nationwide register-based cohort study.
he present study builds on data from two healthcare reg-
stries; (1) The Danish National Health Insurance Service
egister (NHSR), which contains daily information on phys-
otherapy interventions received in private primary care since
990 with the exception of self-paid therapy without reim-
ursement [7], and (2) the Danish National Patient Register
NPR) [8], which includes information on hospital diagnoses
nd contact dates for all in- and outpatient contacts to hos-
itals in Denmark. In NPR there is a primary diagnosis and
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ndividual course of treatment. Diagnoses are coded using the
nternational Classification of Diseases and Related Health
roblems (ICD-10) system [9]. The study was reported as
ecommended in the RECORD checklist (extended STROBE
hecklist) [10].
opulation
In Denmark, national healthcare registries provide
ndividual-based records of contact to the healthcare sys-
em for the entire population [11]. In the present study
ll records of referrals for musculoskeletal physiotherapy
reatment between 1.1.2014 and 31.12.2017 were identi-
ed through the NHSR. Each referral with a contact to
he physiotherapist represented a course  of  treatment  in the
tudy meaning the study population consists of observations
courses of treatment) and the individual patient could be
epresented by several courses of treatment during the study
eriod. The first contact date had to be within 365 days from
he referral date, and each course of treatment had a follow
p period of 180 days from first contact date. The study was
pproved by the Danish Data Protection Agency (No. 1-16-
2-41-19). Under Danish law, this study did not need ethics
pproval (Act on Research Ethics Review of Health Research
rojects, October 2013) [12].
erious  pathology
All records of primary hospital diagnosis within 180 days
rom first contact with the physiotherapist was obtained from
PR, identifying all diagnoses of serious pathology in the
tudy population. Each diagnosis represented a case and
atients could potentially be diagnosed with more than one
erious pathology in the study period. The authors included
ve categories of serious pathology (Table 1). The categories
rimarily represent spine specific pathologies (cauda equina,
pinal fractures, spinal infections and inflammatory diseases
f the spine), but the authors chose to broaden the neoplasm
ategory so that it not only included spinal malignant neo-
lasms but also other malignant neoplasms (cancer) as well
s benign neoplasms (covering benign neoplasm, in situ neo-
lasm and neoplasms of uncertain or unknown behaviour)
ccording to ICD-10.
tatistical  analysis
The flow of observations was described and descriptive
haracteristics of the cohort were presented. Period (180
ays) prevalence proportions of serious pathology were cal-
ulated and presented as prevalence estimates with 95%
onfidence interval (95% CI). The period prevalence refers
o the proportions of patients who had been diagnosed with serious disease during the period of 180 days.
Sensitivity analysis was performed on the prevalence pro-
ortions by including both primary and secondary ICD-10
iagnoses from DNPR. Prevalence estimates were calcu-
98 C.R. Budtz et al. / Physiotherapy 112 (2021) 96–102
Table 1
Categories of serious pathology.
Category Definition ICD-10 Specification
Neoplasms
Malignant neoplasms are cancerous tumours, an abnormal
growth that can grow uncontrolled and spread (metastasize)
to other parts of the body.
DC00-DC96 Malignant neoplasms
In situ neoplasm is a premalignant state in which the growth
of the tumour has not spread to surrounding or distant tissue
in the body.
DD00-DD09 In situ neoplasm
Benign neoplasms are noncancerous growths in the body.
Unlike cancerous tumours, they don’t spread (metastasize)
to other parts of the body.
DD10-DD36 Benign neoplasms
Neoplasms which are currently benign but have
characteristics that make it possible for the tumour to
become malignant.
DD37-DD48 Neoplasms of uncertain behaviour
Cauda Equina Cauda equina syndrome occur when the nerve roots of the
cauda equina are compressed and disrupt motor and sensory
function to the lower extremities and bladder.
DG834 Cauda Equina syndrome
Fracture
Fractures of the vertebra not related to high impact injuries DM484 Fatigue fracture of vertebra
DM485 Collapsed vertebra
DM80 Osteoporosis with pathological
fracture
Infection
Spinal infections occur when bacteria, fungi, or viruses
invade the spinal tissues.
DA17 Tuberculosis of nervous system
DA180 Tuberculosis of bones and joints




Inflammatory diseases related to the spine and vertebra DM023 Reiter’s disease
DM072 Psoriatic spondylitis







































ated only including each patient’s first course of treatment,
hereby changing the cohort from observations to individual
atients. For the categories neoplasm, fracture and inflamma-
ory pathologies, prevalence estimates were calculated and
resented stratified into previously diagnosed with a similar
athology or not. For each of these categories, the following
haracteristics were presented: (1) Gender, (2) age  divided
nto <50/≥50 years of age at first contact to physiotherapist
nd (3) comorbidity  based on the revised Charlson comorbid-
ty index [13,14] using ICD-10 diagnoses from the DNPR the
ast 10 years. The original scale from 0–24 were divided into
 (no comorbidity) and >0 (comorbidity).
All statistical analyses were performed using STATA ver-
ion 15.0 (StataCorp LP, College Station, TX, USA).
esults
A total of 1 708 474 first appointments to a physiotherapist
ere made in the study period. Of these, 130 887 courses ofreatment were excluded because the patient had more than
ne active course of treatment. Additional 8753 courses of
reatment were excluded because the patient died (n  = 7368)




DM46 Other inflammatory spondylopathies
he physiotherapist. A further 130 courses of treatment were
xcluded because of missing data on age and gender. Hence,
he study population consisted of 1 568 704 courses of treat-
ent. The study population was characterized as presented
n Table 2.
The prevalence of neoplasm was 2.11%, of which 1.13%
as malignant neoplasms. The prevalence of cauda equina
yndrome was 0.01%, fractures 0.13%, infections 0.01% and
nflammatory diseases of the spine 0.06%. Changing the
ncluded diagnoses to both primary and secondary diagnoses
ad little impact on the estimated prevalence, changing the
ny serious  pathology  estimate to 2.60% (data not shown).
nly including the first course of treatment for each patient
id not change the estimated prevalence (n  = 1 101 948).
Table 3 presents prevalence estimates of neoplasms, frac-
ure and inflammatory pathology. In all of the pathology
ategories, there was a lower prevalence among patients who
ad not been diagnosed with a similar pathology previously.
mong those not previously diagnosed, patients over the age
f 50 or patients with co-morbidity had higher prevalence
stimates in the neoplasm and fracture pathology categories.
n the inflammatory pathology category only minor differ-
nces in prevalence estimates were detected.
C.R. Budtz et al. / Physiothera
Table 2
Characteristics of study population (n = 1 568 704).
Gender, n (%)
Female 993 959 (63)
Male 574 745 (37)
Age, mean (SD) 51 (19)
CCI (0–24), n (%)
0 1 357 039 (87)
1–24 211 795 (13)
Course of treatment, median [IQR]
Days from referral to first treatment 8 [2 to 19]
Treatment days in course of treatment 5 [3 to 10]
Prevalence of serious pathology, % (95%CI)
Neoplasm 2.11 (2.10 to 2.13)
Cauda equina 0.01 (0.00 to 0.01)
Fracture 0.13 (0.12 to 0.13)
Infection 0.01 (0.01 to 0.01)
Inflammatory 0.06 (0.06 to 0.07)



















































































in our sample as compared to previous studies includingbbreviations: CCI, Charlson Comorbidity Index; CI, Confidence Inter-
al; IQR, Inter Quartile Range; n, number of observations; SD, Standard
eviation.
iscussion
This is the first study to estimate the prevalence of serious
athology among patients with musculoskeletal conditions
reated in primary care physiotherapy. The overall prevalence
f serious pathology was 2.30%. The prevalence of neo-
lasm was 2.11%, of which 1.13% was malignant neoplasms.
he prevalence of cauda equina syndrome, fractures, infec-
ions and inflammatory pathology of the spine was 0.01%,
.13%, 0.01% and 0.06% respectively. When previously
iagnosed patients were excluded, the prevalence of malig-
ant neoplasm, benign neoplasm, fracture and inflammatory
athology was 0.64%, 0.80%, 0.10% and 0.05% respectively.
trengths  and  limitations
A major strength of the study is, that the included cohort
epresents all patients seen in primary care physiotherapy
ecause of musculoskeletal conditions, thus no bias due
o selection was present. However, patients who died or
igrated within 180 days from their first physiotherapy con-
act were excluded. Because the study estimated prevalence
f serious (and possibly fatal) pathologies, patients might
ave died from neoplasms, for example, which means the esti-
ated prevalence could be underestimated. Also, the authors
ave no information about possible diagnoses in patients who
igrated. Nevertheless, taking into account the relatively few
atients that were excluded, the possible underestimation
ould probably be small. Also misclassifications of serious
athology could have occurred. Although the NPR is based
n ICD-10 diagnoses, which enables transparent categoriza-
ions of serious pathology, patients could initially present
ith a suspected serious pathology, but eventually be diag-
osed with another condition. If the initial diagnosis is not
orrectly amended, afterwards, there is a risk of misclassifica-
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otential misclassification is however thought to be small. To
void such misclassifications in the neoplasm category, the
uthors could have used the Danish Cancer Registry (DCR)
15]. In the DCR only verified diagnoses of cancer (malig-
ant neoplasms) are recorded. However, the DCR does not
ontain information on benign neoplasms. The authors chose
o include both benign and malignant neoplasms, as the ini-
ial distinction between symptoms of malignant or benign
eoplasm can be very difficult. The symptoms will often
epend on the location but more general symptoms (such
s fatigue, loss of appetite or fever) may also occur in any
ype of neoplasm. This possible overestimation would, how-
ver, still be based on a suspicion of serious pathology which
eans the patient should be referred to further evaluation in
econdary care. Furthermore, as benign neoplasms also can
everely affect the patients’ general health status the detec-
ion of overall symptoms of neoplasms and timely referral are
mportant. If the physiotherapist has even a vague suspicion
hat the patient might have a serious pathology the physio-
herapist should send the patient back to the GP for further
nvestigation.
In the NHSR it is not possible to extract reasons for
eferrals, meaning the authors cannot categorize the mus-
uloskeletal conditions into specific diagnostic groups. It
owever seems plausible, that the prevalence of spine spe-
ific serious pathologies, such as fractures and cauda equina
yndrome, are higher among patients with spine specific
onditions. Unfortunately, this hypothesis could not be inves-
igated in the present study.
nterpretation  of  the  results
To our knowledge, this is the first study investigating the
revalence of serious pathology in primary care patients with
 wide range of musculoskeletal conditions as compared to
pine specific conditions. The neoplasm estimate of 2.11%
s the largest contributor to the overall estimate of 2.30%.
his indicates that screening for serious pathology in phys-
otherapy practise perhaps could benefit from concentrating
ore on screening for neoplasm. Also the results as expected
howed, that excluding patients with a previous diagnose in
he same pathology category resulted in significantly smaller
revalence estimates. The authors however chose to include
he previously diagnosed patients in the estimates as this is
ery important information for the physiotherapist to con-
ider when screening patients for serious pathologies. This
ay be most important for the neoplasm or fracture category,
s it could indicate a relapse of disease or the presence of
steoporosis. Surprisingly, the prevalence of spinal fractures
as only 0.13% which is significantly lower than previously
eported estimates of around 4%. This could be explained
y the broad range of musculoskeletal conditions includedpine related disorders only. Moreover, as our population was
eferred to physiotherapy it is likely that some fractures have
een picked up in the initial screening by the GP. The over-
100 C.R. Budtz et al. / Physiotherapy 112 (2021) 96–102
Table 3
Prevalence of neoplasm, fracture and inflammatory pathology within 180 days from first treatment date divided into courses of treatment with no previous
diagnosis and previously diagnosis.
No previous diagnosis Previously diagnosed
Observations (n) Prevalence (%) CI 95% Observations (n) Prevalence (%) CI 95%
Malignant neoplasm
Overalla 1 451 923 0.64 (0.63 to 0.65) 116 781 7.26 (7.11 to 7.41)
Gender
Female 915 969 0.61 (0.59 to 0.62) 77 990 6.45 (6.28 to 6.62)
Male 535 954 0.69 (0.67 to 0.72) 38 791 8.89 (8.61 to 9.18)
Age
<50 685 545 0.13 (0.12 to 0.14) 23 304 3.63 (3.39 to 3.88)
≥50 766 378 1.10 (1.07 to 1.12) 93 477 8.16 (7.99 to 8.34)
Comorbidity
No 1 298 554 0.49 (0.48 to 0.50) 58 368 1.55 (1.45 to 1.65)
Yes 153 369 1.90 (1.83 to 1.96) 58 413 12.97 (12.69 to 13.24)
Benign neoplasm
Overalla 1 451 923 0.80 (0.78 to 0.81) 116 781 3.93 (3.82 to 4.04)
Gender
Female 915 969 0.86 (0.84 to 0.88) 77 990 3.79 (3.66 to 3.93)
Male 535 954 0.69 (0.57 to 0.72) 38 791 4.21 (4.01 to 4.41)
Age
<50 685 545 0.47 (0.58 to 0.61) 23 304 4.24 (3.98 to 4.50)
≥50 766 378 1.09 (1.06 to 1.11) 93 477 3.85 (3.73 to 3.98)
Comorbidity
No 1 298 554 0.74 (0.73 to 0.76) 58 368 4.71 (4.54 to 4.89)
Yes 153 369 1.23 (1.18 to 1.29) 58 413 3.15 (3.01 to 3.29)
Fracture
Overalla 1 558 255 0.10 (0.10 to 0.11) 10 579 3.89 (3.53 to 4.28)
Gender
Female 984 763 0.13 (0.12 to 0.14) 9196 3.96 (3.57 to 4.38)
Male 573 362 0.05 (0.05 to 0.06) 1383 3.47 (2.57 to 4.58)
Age
<50 708 677 0.00b (0.00 to 0.00) 172 23.25 (0.63 to 58.47)
≥50 849 448 0.18 (0.17 to 0.19) 10 407 3.92 (3.56 to 4.31)
Comorbidity
No 1 350 228 0.08 (0.07 to 0.08) 6811 3.83 (3.39 to 4.32)
Yes 208 027 0.24 (0.22 to 0.27) 3768 4.01 (3.40 to 4.68)
Inflammatory
Overalla 1 563 938 0.05 (0.04 to 0.05) N/Ac
Gender
Female 991 140 0.04 (0.03 to 0.04) N/A
Male 572 671 0.06 (0.05 to 0.07) N/A
Age
<50 706 530 0.06 (0.05 to 0.06) N/A
≥50 857 281 0.04 (0.03 to 0.04) N/A
Comorbidity
No 1 353 102 0.04 (0.04 to 0.05) N/A
Yes 210 836 0.06 (0.05 to 0.07) N/A
Abbreviations: CI: Confidence Interval.
a Malignant and benign neoplasm: diagnosed with any type of neoplasm 0–3 years prior date of first contact; fracture: diagnosed with a similar fracture in












that the prevalence of serious pathology among primaryb Rounded to two decimals.
c N/A: Not applicable as this is a group of chronic patients.
ll prevalence of both malignant and benign neoplasm was
arkedly reduced, when only looking at courses of treatment
here the patient had not previously been diagnosed with
eoplasm. In the fracture category the change was more mod-
st. Prevalence estimates of inflammatory pathology among
atients previously diagnosed with a similar pathology was
mitted, as this is a group of lifelong chronic diseases making
revalence estimates less useful.
c
n
Among patients with LBP it has been acknowledged, that
pproximately 1% have an undiscovered serious pathology
3,4,16,17]. This estimate is however based on relatively
ld and small studies and more recent evidence suggestsare LBP patients may be as high as 6% [18]. Unfortu-
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hallenged by small study populations resulting in inaccurate
r missing estimates because few or none of the partici-
ants were diagnosed with the specific serious pathologies
6,19]. Nevertheless, the results of the present study sug-
est, that the previously acknowledged estimate may be
oo low. All the included patients in the present study had
een referred by the GP, meaning the GP had screened
or serious pathology as a natural part of their consulta-
ion. Despite that, 2.30% of the patients were diagnosed
ith serious pathology within 180 days from their first con-
act. Although the authors cannot assume that all of these
atients would have had symptoms of serious pathology,
t remains certain that the physiotherapists cannot solely
ely on the initial screening from the GP, because these
erious conditions may cause symptoms that develop over
ime.
eneralisability  of  the  results
The external validity of the study is considered excellent,
s the study was based on Danish national healthcare reg-
stries, which covers the total Danish population. Because of
he study power and completeness of the Danish healthcare
egistries, the prevalence of different categories of seri-
us pathologies form a very robust and accurate estimation
n the group of patients with musculoskeletal conditions
reated in primary care physiotherapy. It should however
e taken into account, that the population of patients with
usculoskeletal conditions may vary significantly between
ountries as a result of different healthcare systems and treat-
ent pathways. Also, the prevalence of serious pathology in
 population is of course affected by the prevalence of eti-
logical factors like for example tuberculosis in the studied
opulation.
onclusion
The prevalence of serious pathology among patients
eferred by GPs to musculoskeletal physiotherapy was
.30%. This means, that although serious pathology is rare,
t is more frequent than the guideline endorsed prevalence
stimates suggests.
ontribution  of  the  paper
 The study is the first to estimate the prevalence of serious
pathology in a group of patients referred by the general
practitioner to primary care physiotherapy with a broad
range of musculoskeletal disorders. The study is based on Danish Healthcare Registries, with
a large data set, limited risk of bias and excellent general-
isability of the results.py 112 (2021) 96–102 101
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